ERBB2 and breast carcinoma: In the SUMMIT and MutHER trials, dual HER2-targeting to address the increase in HER2 signaling was explored by adding trastuzumab to neratinib, with the anti-estrogen fulvestrant in HR-positive breast cancer in an effort to circumvent resistance [13–15].